Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 196

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients

Open access
Noureddin, Mazen, Yates, Katherine P., Vaughn, Ivana A., Neuschwander-Tetri, Brent A., Sanyal, Arun J., McCullough, Arthur, Merriman, Raphael, Hameed, Bilal, Doo, Edward, Kleiner, David E., Behling, Cynthia, Loomba, Rohit·2013·Hepatology

Abstract

The characteristics of nonalcoholic fatty liver disease (NAFLD) in elderly patients are unknown. Therefore, we aimed to examine the differences between elderly and nonelderly patients with NAFLD and to identify determinants of nonalcoholic steatohepatitis (NASH) and advanced fibrosis (bridging fibrosis or cirrhosis) in elderly patients. This is a cross-sectional analysis of adult participants who were prospectively enrolled in the NASH Clinical Research Network studies. Participants were included based on availability of the centrally reviewed liver histology data within 1 year of enrollment, resulting in 61 elderly (age ≥65 years) and 735 nonelderly (18-64 years) participants. The main outcomes were the presence of NASH and advanced fibrosis. Compared to nonelderly patients with NAFLD, elderly patients had a higher prevalence of NASH (56% versus 72%, P = 0.02), and advanced fibrosis (25% versus 44%, P = 0.002). Compared to nonelderly patients with NASH, elderly patients with NASH had higher rates of advanced fibrosis (35% versus 52%, P = 0.03), as well as other features of severe liver disease including the presence of ballooning degeneration, acidophil bodies, megamitochondria, and Mallory-Denk bodies ( P ≤ 0.05 for each). In multiple logistic regression analyses, independent determinants of NASH in elderly patients included higher aspartate aminotransferase (AST) (odds ratio [OR] = 1.12, P = 0.007) and lower platelets (OR = 0.98, P = 0.02); and independent determinants of advanced fibrosis included higher AST (OR = 1.08, P = 0.007), lower alanine aminotransferase value (OR = 0.91, P = 0.002), and an increased odds of having low high-density lipoprotein (OR = 8.35, P = 0.02). Conclusion: Elderly patients are more likely to have NASH and advanced fibrosis than nonelderly patients with NAFLD. Liver biopsy may be considered in elderly patients and treatment should be initiated in those with NASH and advanced fibrosis. (Hepatology 2013;58:1644–1654)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.26465

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 36

  1. Kim, 2002, Burden of liver disease in the United States: summary of a workshop., Hepatology, 36, 227242, 10.1053/jhep.2002.34734 · DOI · Paper page
  2. Clark, 2003, The prevalence and etiology of elevated aminotransferase levels in the United States., Am J Gastroenterology, 98, 960967, 10.1111/j.1572-0241.2003.07486.x · doi:10.1111/j.1572-0241.2003.07486.x · Paper page
  3. Williams, 2011, Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middleaged population utilizing ultrasound and liver biopsy: a prospective study., Gastroenterology, 140, 124131, 10.1053/j.gastro.2010.09.038 · DOI · Paper page
  4. Ratziu, 2010, A position statement on NAFLDNASH based on the EASL 2009 special conference., J Hepatol, 53, 372384, 10.1016/j.jhep.2010.04.008 · DOI · Paper page
  5. Browning, 2004, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity., Hepatology, 40, 13871395, 10.1002/hep.20466 · DOI · Paper page
  6. Chen, 2007, Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan., J Gastroenterol Hepatol, 22, 14821489, 10.1111/j.1440-1746.2006.04615.x · DOI
  7. Harrison, 2003, The natural history of nonalcoholic fatty liver disease: a clinical histopathological study., Am J Gastroenterol, 98, 20422047, 10.1111/j.1572-0241.2003.07659.x · doi:10.1111/j.1572-0241.2003.07659.x · Paper page
  8. Brunt, 2009, Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLDClinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network., Hepatology, 49, 809820, 10.1002/hep.22724 · DOI · Paper page
  9. CarterKent, 2011, Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease., J Pediatr Gastroenterol Nutr, 52, 190197
  10. Alkhouri, 2012, Development and validation of a new histological score for pediatric nonalcoholic fatty liver disease (NAFLD)., J Hepatol, 57, 13121318, 10.1016/j.jhep.2012.07.027 · DOI
  11. Schwimmer, 2005, Histopathology of pediatric nonalcoholic fatty liver disease., Hepatology, 42, 641649, 10.1002/hep.20842 · DOI · Paper page
  12. Lonardo, 2006, Fatty liver, carotid disease and gallstones: a study of agerelated associations., World J Gastroenterol, 12, 58265833, 10.3748/wjg.v12.i36.5826 · DOI
  13. Suzuki, 2005, Chronological development of elevated aminotransferases in a nonalcoholic population., Hepatology, 41, 6471, 10.1002/hep.20543 · DOI · Paper page
  14. Kagansky, 2004, Nonalcoholic fatty liver diseasea common and benign finding in octogenarian patients., Liver Int, 24, 588594, 10.1111/j.1478-3231.2004.0969.x · DOI
  15. Frith, 2009, Nonalcoholic fatty liver disease in older people., Gerontology, 55, 607613, 10.1159/000235677 · DOI · Paper page
  16. Arias, 2008, U.S. decennial life tables for 19992001, United States life tables., National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics Natl Vital Stat Rep, 57, 136
  17. Arias, 2010, United States life tables, 2005. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics., Natl Vital Stat Rep, 58, 1132
  18. Arias, 2010, United States life tables, 2006. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics., Natl Vital Stat Rep, 58, 140
  19. Chalasani, 2009, Pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis: PIVENS trial design., Contemp Clin Trials, 30, 8896, 10.1016/j.cct.2008.09.003 · DOI · Paper page
  20. NeuschwanderTetri, 2010, Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease., Hepatology, 52, 913924
  21. Chaurasia, 2012, Using AIC in multiple linear regression framework with multiply imputed data., Health Serv Outcomes Res Methodol, 12, 219233, 10.1007/s10742-012-0088-8 · DOI
  22. Paul, 2012, Standardizing the power of the HosmerLemeshow goodness of fit test in large data sets., Stat Med, 32, 6780
  23. Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD., Hepatology, 45, 846854, 10.1002/hep.21496 · DOI · Paper page
  24. Argo, 2009, Epidemiology and natural history of nonalcoholic steatohepatitis., Clin Liver Dis, 13, 511531, 10.1016/j.cld.2009.07.005 · DOI · Paper page
  25. Okanoue, 2011, Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan., J Gastroenterol Hepatol, 26, 153162
  26. GutierrezGrobe, 2010, Prevalence of non alcoholic fatty liver disease in premenopausal, postmenopausal and polycystic ovary syndrome women. The role of estrogens., Ann Hepatol, 9, 402409
  27. Hashimoto, 2011, Prevalence, gender, ethnic variations, and prognosis of NASH., J Gastroenterol, 46, 6369
  28. Fan, 2009, Epidemiology of nonalcoholic fatty liver disease in China., J Hepatol, 50, 204210, 10.1016/j.jhep.2008.10.010 · DOI · Paper page
  29. Harrison, 2008, Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease., Gut, 57, 14411447, 10.1136/gut.2007.146019 · DOI · Paper page
  30. Ford, 2002, Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey., JAMA, 287, 356359, 10.1001/jama.287.3.356 · DOI · Paper page
  31. Permutt, 2012, Correlation between liver histology and novel magnetic resonance imaging in adult patients with nonalcoholic fatty liver disease MRI accurately quantifies hepatic steatosis in NAFLD., Aliment Pharmacol Ther, 36, 2229, 10.1111/j.1365-2036.2012.05121.x · DOI · Paper page
  32. Adams, 2005, The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies., J Hepatol, 42, 132138, 10.1016/j.jhep.2004.09.012 · DOI · Paper page
  33. Chalasani, 2012, The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology., Gastroenterology, 142, 15921609, 10.1053/j.gastro.2012.04.001 · DOI · Paper page
  34. Zein, 2011, Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebocontrolled trial., Hepatology, 54, 16101619, 10.1002/hep.24544 · DOI · Paper page
  35. NeuschwanderTetri, 2003, Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPARgamma ligand rosiglitazone., Hepatology, 38, 10081017
  36. Van Wagner, 2011, Pentoxifylline for the treatment of nonalcoholic steatohepatitis: a randomized controlled trial., Ann Hepatol, 10, 277286, 10.1016/S1665-2681(19)31539-X · DOI · Paper page

Cited by

See all 196

Metadata

Authors
Noureddin, M., Yates, K. P., Vaughn, I. A., Neuschwander-Tetri, B. A., Sanyal, A. J., McCullough, A., Merriman, R., Hameed, B., Doo, E., Kleiner, D. E., Behling, C., & Loomba, R.
Venue
Hepatology
Published
2013-11
Volume
58
Issue
5
Pages
1644-1654
ISSN
0270-9139 (ISSN-L)
OpenAlex
W1952814383
Cited by
196
References
10
FWCI
9.73
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (U01DK061718, U01DK061728, U01DK061731, U01DK061732, U01DK061734, U01DK061737, U01DK061738, U01DK061730, U01DK061713)
  • Clinical Research Centers or Clinical and Translational Science (UL1RR024989, M01RR000750, UL1RR02413101, M01RR000827, UL1RR02501401, M01RR000065, M01RR020359)
  • American Gastroenterological Association (AGA)
  • Foundation - Sucampo - ASP Designated Research Award in Geriatric Gastroenterology
  • Atlantic Philanthropies, Inc
  • Association of Specialty Professors
  • American Gastroenterological Association (K23DK090303)
  • intramural research program of the NIH
  • National Cancer Institute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. https://app.cochat.ai/papers/10.1002/hep.26465
The paper
Noureddin, M., Yates, K. P., Vaughn, I. A., Neuschwander-Tetri, B. A., Sanyal, A. J., McCullough, A., Merriman, R., Hameed, B., Doo, E., Kleiner, D. E., Behling, C., & Loomba, R. (2013). Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. https://doi.org/10.1002/hep.26465

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.